Table 4. Sorafenib dose modifications.
Dose modification | BCLC stage B (N = 11) | BCLC stage C (N = 17) | Overall (N = 28) |
Dose delay, N (%) | 6 (55) | 10 (59) | 16 (57) |
Dose further delay, N (%) | 0 | 1 (6) | 1 (4) |
Dose reduction, N (%) | 7 (64) | 4 (24) | 11 (39) |
Dose resumed to starting dose, N (%) | 1 (9) | 2 (12) | 3 (11) |
Dose permanently discontinued following modification, N (%) | 0 | 1 (6) | 1 (4) |